Benzinga | Jul 22, 2020 08:02AM EDT

SCYNEXIS Announces Four Posters Presented At ASM Microbe 2020 Highlighting Potential Clinical Utility Of Ibrexafungerp

JERSEY CITY, N.J., July 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of four posters at the American Society for Microbiology (ASM) Microbe 2020 held virtually from June through August. The posters, presented as part of the ASM Microbe Online 2020 Summer of Science program, now available online, highlight the potential clinical utility of ibrexafungerp. Ibrexafungerp is the first representative of a new class of antifungal agents called triterpenoids, which are broad-spectrum, fungicidal, and designated by the suffix "-fungerp". Following the successful completion of its VANISH Phase 3 program, the Company plans to submit a new drug application (NDA) for ibrexafungerp as a treatment for vaginal yeast infections in the second half of this year, while advancing several late-stage programs for the treatment of life-threatening fungal infections in hospitalized patients.



"Fungal infections are increasingly common and often represent serious public health threats, yet there are limited treatment options. The clinical and preclinical studies presented at ASM Microbe 2020 highlight ibrexafungerp's potential across a broad spectrum of fungal infections, including resistant strains," said Marco Taglietti, M.D., Chief Executive Officer of SCYNEXIS. "As superbugs flourish and antifungal drug development dwindles, we remain committed to advancing ibrexafungerp, our novel antifungal, for patients in the hospital and community settings. The COVID-19 pandemic is a powerful reminder about the importance of continuous development of anti-infectives."

Poster Details:

Treatment Outcomes of Oral Ibrexafungerp in Patients with SevereTitle Fungal Infections, Refractory to or Intolerant of Standard of Care Antifungals: Results from the Phase 3 FURI Study Second Interim AnalysisSession Virtual 380 - CIV01 Clinical Studies of Adult Infectious Diseases including Epidemiology and Clinical TrialsAuthors N. Azie, D. Angulo An interim analysis of 21 patients from the Phase 3 clinical study evaluating ibrexafungerp for the treatment of patients intolerant to the standard of care treatment for Candida infections (FURI Study)Highlights found that treatment with oral ibrexafungerp showed significant clinical benefit in 81% of patients, with 12 (57%) patients achieving a complete or partial response and 5 (24%) patients with stable disease. [Link to study details]